iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual SymposiumGlobeNewsWire • 04/11/24
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk EvaluationGlobeNewsWire • 04/09/24
iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology MeetingGlobeNewsWire • 04/08/24
iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise ScaleGlobeNewsWire • 04/02/24
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform OfferingsGlobeNewsWire • 02/28/24
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)GlobeNewsWire • 02/27/24
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024GlobeNewsWire • 02/27/24
iCAD's AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE HealthcareGlobeNewsWire • 11/28/23
iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart DiseaseGlobeNewsWire • 11/27/23
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to ElektaGlobeNewsWire • 10/23/23
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year AssessmentGlobeNewsWire • 08/16/23